Prodromal Radyasyon Sendromu, Lethal ve Subletal Dozlar ve Terapötik Yaklaşım
Özet
Prodromal Radyasyon Sendromu (PRS), radyasyon maruziyeti sonrası dakikalar veya günler içinde başlayan ve Akut Radyasyon Sendromu’nun (ARS) ilk aşamasını oluşturan, bulantı, kusma, ishal ve eritem gibi nonspesifik semptomlarla seyreden heterojen bir klinik tablodur. Işınlamanın patofizyolojisinde, özellikle mitoz fazındaki hızlı bölünen hematopoetik kök hücreler ile gastrointestinal sistem hücrelerinde meydana gelen ve tamiri oldukça güç olan DNA çift sarmal kırıkları temel rol oynamaktadır. Erken dönemde ortaya çıkan bulgular deterministik etkiyle doz bağımlı olarak şiddetlenirken, maruziyet dozu arttıkça kusma ve baş ağrısı gibi semptomların başlangıç süresi kısalmaktadır. Klinik tablonun yönetiminde, maruz kalınan dozun fiziksel, biyolojik veya klinik dozimetreyle (özellikle lenfosit sayısındaki düşüş hızı ve kromozom aberasyon testleri) doğru tahmini kritik önem taşır. Tedavi yaklaşımında METREPOL kılavuzuna göre triyaj yapılarak hafif vakalar ayaktan takip edilirken, şiddetli maruziyetlerde kapsamlı hastane yatışı, sıvı-elektrolit replasmanı, geniş spektrumlu proflaktik antibiyotikler, büyüme faktörleri (G-CSF) ve gerekli durumlarda HLA uyumlu kök hücre nakli gibi agresif destek tedavileri uygulanmaktadır.
Prodromal Radiation Syndrome (PRS) is the initial stage of Acute Radiation Syndrome (ARS), characterized by a heterogeneous clinical presentation including nausea, vomiting, diarrhea, and erythema, which manifests within minutes to days following radiation exposure. The pathophysiology relies on radiation-induced DNA double-strand breaks that are highly difficult to repair, primarily affecting rapidly dividing hematopoietic stem cells and gastrointestinal tract cells during their mitotic phase. Early clinical signs emerge as deterministic effects dependent on the dose, and as the exposure level increases, the onset time of symptoms such as vomiting and headache significantly shortens. Accurate dose estimation through physical, biological, or clinical dosimetry—particularly via lymphocyte depletion kinetics and chromosome aberration analysis—is vital for effective clinical management. According to METREPOL guidelines, treatment strategies involve systematic triage where mild cases are managed outpatiently, whereas severe exposures require extensive hospitalization, fluid-electrolyte replacement, broad-spectrum prophylactic anti-infectives, growth factors (G-CSF), and HLA-matched hematopoietic stem cell transplantation as part of comprehensive supportive care.
Referanslar
De-Coursey E. Human pathological anatomy of ionizing radiation effects of the atomic bomb explosions. Mil Surg. 1948;102:427–432.
National Council on Radiation Protection and Measurements (NCRP) (2001). Management of Terrorist Events Involving Radioactive Material. NCRP Report No. 138. NCRP. Bethesda, MD.
International Atomic Energy Agency. Diagnosis and treatment of radiation injuries. Safety reports series 2. Vienna: IAEA. 1998.
Dörr H, Meineke V. Acute radiation syndrome caused by accidental radiation exposure - therapeutic principles. BMC Medicine. 2011; 9:126.
López M, Martín M. Medical management of the acute radiation syndrome. Rep Pract Oncol Radiother. 2011;16(4):138-146.
Donnelly EH, Nemhauser JB, Smith JM, et al. Acute Radiation Syndrome: Assessment and Management. South Med J. 2010;103(6):541-546.
Akashi M, Hirama T, Tanosaki S, Kuroiwa N, Nakagawa K, Tsuji H, et al. Initial symptoms of acute radiation syndrome in the JCO criticality accident in Tokai-mura. J Radiat Res. 2001, no. Suppl : 157-166.
Lutgens LC, Deutz N, Granzier-Peeters R, et al. Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients. Int J Radiat Oncol Biol Phys. 2004;60:275–285.
Kashima HK, Kirkham WR, Andrews JR. Post-irradiation sialadenitis: a study of the clinical features, histopathologic changes and serum enzyme variations following irradiation of human salivary glands. Am J Roentgenol. 1965;94: 271–291.
Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961;14:213–222.
Garau MM, Calduchb AL, López EC. Radiobiology of the acute radiation syndrome. Rep Pract Oncol Radiother. 2011;16(4):123-130.
Anno GH, Young RW, Bloom RM, Mercier JR. Dose response relationships for acute ionizing-radiation lethality. Health Phys. 2003;84:565-575.
Goans RE, Holloway EC, Berger ME, Ricks RC. Early dose assessment following severe radiation accidents. Health Phys. 1997;72:513–518.
Armed Forces Radiobiology Research Institute (AFRRI) (2003). Medical Management of Radiological Casualties Handbook (second ed). Bethesda, MD, AFRRI.
Prasad KN. (1995). Handbook of Radiobiology (second ed) . New York, NY, CRC Press, Inc.
Farese AM, Cohen MV, Katz BP, Smith CP, Jakson W, Cohen DM, et al. A nonhuman primate model of the hematopoietic acute radiation syndrome plus medical management. Health Phys. 2012;103(4):367-382.
Elliott TB, Deutz NE, Gulani J, Koch A, Olsen CH, Christensen C, et al. Gastrointestinal Acute Radiation Syndrome in Göttingen Minipigs (Sus Scrofa Domestica). Comp Med. 2014;64(6): 456-463.
Guo H, Chou WC, Lai Y, Liang K, Tam JW, Brickey WJ, et al. Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites. Science. 2020;370(6516).
Mucaki EJ, Shirley BC, Rogan PK. Improved radiation expression profiling in blood by sequential application of sensitive and specific gene signatures. Int J Radiat Biol. 2021;1-18.
Port M, Haupt J, Ostheim P, Majewski M, Combs SE, Atkinson M, et al. Software Tools for the Evaluation of Clinical Signs and Symptoms in the Medical Management of Acute Radiation Syndrome-A Five-year Experience. Health Phys. 2021; 120(4):400-409.
Fliedner TM, Friesecke I, Beyrer K (2001). Medical Management of Radiation Accidents: Management of the Acute Radiation Syndrome (METREPOL)British Institute of Radiology, Oxford.
RITN Acute Radiation Syndrome Treatment Guidelines. https://remm.hhs.gov/RITN-ARS-Treatment-Guidelines-21Oct-FINAL.pdf
